Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection

The multidrug-resistant (MDR) human immunodeficiency virus 1 (HIV-1) infection is an unmet medical need. HIV-1 capsid plays an important role at different stages of the HIV-1 replication cycle and is an attractive drug target for developing therapies against MDR HIV-1 infection. Lenacapavir (LEN) is...

全面介紹

書目詳細資料

Principais autores:	Tafadzwa Dzinamarira, Mazen Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A. Rabaan, Amal H. Alfaraj, Bashayer M. AlShehail, Nouf Alotaibi, Shams M. AlShehail, Mohd Imran
格式:	Artigo
語言:	Inglês
出版:	MDPI AG 2023-05-01
叢編:	Medicina
主題:	Lenacapavir Sunlenca GS-6207 HIV-1 capsid patent prospects
在線閱讀:	https://www.mdpi.com/1648-9144/59/6/1041
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!